Ranking Invest
Switch to English

Madrigal Pharmaceuticals, Inc.

Segmento: Healthcare Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Indicadores Básicos

Valor de Mercado

$ 8.46 Bi

IVR

-

IVR2

-0.15

Índices de Previsibilidade

Faturamento

0.91

Lucro

0.17

Margem

1.18

Índices de Tendência

Faturamento

8.28

Lucro

-6.20

Margem

-4.39

Índices de Endividamento

DIV/PAT

-0.09

DIV/L4T

0.16

Dívida Líquida

-$ 63.88 Mi

Patrimônio Líquido

$ 710.64 Mi

L4T

-$ 391.59 Mi

MM4T

-330.27%

Dívidas
Gráfico Lucro/Faturamento X Trimestre